tumor antigens

(redirected from tumour antigens)

tu·mor an·ti·gens

1. antigens that may be frequently associated with tumors or may be specifically found on tumor cells of the same origin (tumor specific);
2. tumor antigens may also be associated with replication and transformation by certain DNA tumor viruses, including adenoviruses and papovaviruses.
Synonym(s): neoantigens (2)

See also: T antigens.

tu·mor an·ti·gens

(tū'mŏr an'ti-jenz)
1. Those antigens that may be frequently associated with tumors or may be specifically found on tumor cells of the same origin (tumor specific).
2. Tumor antigens may also be associated with replication and transformation by certain DNA tumor viruses, including adenoviruses and papovaviruses.
See also: T antigens
Synonym(s): neoantigens, tumour antigens.
References in periodicals archive ?
Tumour antigens, unique proteins on the surface of a tumour, are potential targets for a normal immune response against cancer.
But some of these tumour antigens are also expressed on normal cells, inching personalized therapy back to the original problem.
cells ex vivo, pulsing them with tumour antigens and re-infusing them.
express helper cell and CTL epitopes from tumour antigens over-expressed
Several groups have demonstrated successful vaccination by growing dendritic cells ex vivo, pulsing them with tumour antigens and re-infusing them.
An ImmunoBody is a DNA vaccine encoding a human antibody or fusion protein engineered to express helper cell and CTL epitopes from tumour antigens over-expressed by cancer cells.
While chronic inflammation that is often associated with the recruitment of innate immune cells to tumours promotes cancer, acute inflammatory responses can counteract immunosuppressive mechanisms operating in many tumours and allow tumour infiltration by lymphocytes to induce adaptive immune responses against tumour antigens.
Because these immunotherapeutics include the entire antigenic repertoire of the patient's tumour, they preclude the need to identify or isolate specific tumour antigens.
Such a cancer immunotherapeutic can treat those patients without known tumour antigens (no original tumour site) and from whom insufficient tumour material can be obtained and used as a source to create the personalized treatment.
The therapeutic platform combines a completely novel proprietary and IP-protected approach - the utilisation of a bacterial danger signal in combination with the patient's tumour antigens - with a proven successful concept (dendritic cells) to mobilise the patients' immune system to combat the disease.
An ImmunoBody[R] is a human antibody or fusion protein engineered to express helper cell and CTL epitopes from tumour antigens over-expressed by cancer cells.
An ImmunoBody[R] is a DNA vaccine encoding a human antibody or fusion protein engineered to express helper cell and CTL epitopes from tumour antigens over-expressed by cancer cells.